English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 38 Help

Selected(0)Clear Items/Page:    Sort:
Supramolecular prodrug vesicles for selective antimicrobial therapy employing a chemo-photodynamic strategy Journal article
Sun, Hao, Li, Shengke, Liu, Qian, Zuo, Minzan, Tian, Xueqi, Wang, Kaiya, Hu, Xiao Yu. Supramolecular prodrug vesicles for selective antimicrobial therapy employing a chemo-photodynamic strategy[J]. Chinese Chemical Letters, 2025, 36(3).
Authors:  Sun, Hao;  Li, Shengke;  Liu, Qian;  Zuo, Minzan;  Tian, Xueqi; et al.
Favorite | TC[WOS]:2 TC[Scopus]:1  IF:9.4/7.3 | Submit date：2025/01/22
Cavitand  Combination Therapy  Host-guest Complex  Selective Antibacterial Activity  Supramolecular Prodrug  
Targeting hexokinase 2 to enhance anticancer efficacy of trichosanthin in HeLa and SCC25 cell models Journal article
Zhou, Yan, Ran, Maoxin, Shan, Wenying, Wang, Kaifang, Sha, Ou, Tam, Kin Yip. Targeting hexokinase 2 to enhance anticancer efficacy of trichosanthin in HeLa and SCC25 cell models[J]. ADMET and DMPK, 2024, 12(6), 821-841.
Authors:  Zhou, Yan;  Ran, Maoxin;  Shan, Wenying;  Wang, Kaifang;  Sha, Ou; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.4/2.8 | Submit date：2025/01/13
Ribosome-inactivating Protein  Glycolysis  Drug Combination  Synergistic Effect  Cancer Therapy  
Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma Journal article
Yao, Yawen, Hu, Yue, Meng, Xinwang, Feng, Fenyan, Xu, Feng, Wang, Guangji, Yu, Hua, Li, Juan. Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma[J]. Pharmaceutical Science Advances, 2024, 2, 100046.
Authors:  Yao, Yawen;  Hu, Yue;  Meng, Xinwang;  Feng, Fenyan;  Xu, Feng; et al.
Favorite | TC[Scopus]:1 | Submit date：2024/12/05
Sorafenib  Docetaxel  Dual-targeting Liposomes  Combination Therapy  Advanced Hepatocellular Carcinoma  
The enhancing effects of selenomethionine on harmine in attenuating pathological cardiac hypertrophy via glycolysis metabolism Journal article
Chen, Qi, Wang, Wen Yan, Xu, Qing Yang, Dai, Yan Fa, Zhu, Xing Yu, Chen, Zhao Yang, Sun, Ning, Leung, Chung Hang, Gao, Fei, Wu, Ke Jia. The enhancing effects of selenomethionine on harmine in attenuating pathological cardiac hypertrophy via glycolysis metabolism[J]. Journal of Cellular and Molecular Medicine, 2024, 28(19), e70124.
Authors:  Chen, Qi;  Wang, Wen Yan;  Xu, Qing Yang;  Dai, Yan Fa;  Zhu, Xing Yu; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:4.3/5.0 | Submit date：2024/10/10
Cardiac Hypertrophy  Combination Therapy  Glycolysis Metabolism  Harmine  Selenomethionine  
Combined inhibition of pyruvate dehydrogenase kinase 1 and hexokinase 2 induces apoptsis in non-small cell lung cancer cell models Journal article
Guo, Yizhen, Lu, Xianchen, Zhou, Yan, Chen, Wen Hua, Tam, Kin Yip. Combined inhibition of pyruvate dehydrogenase kinase 1 and hexokinase 2 induces apoptsis in non-small cell lung cancer cell models[J]. Experimental Cell Research, 2023, 433(2), 113830.
Authors:  Guo, Yizhen;  Lu, Xianchen;  Zhou, Yan;  Chen, Wen Hua;  Tam, Kin Yip
Favorite | TC[WOS]:0 TC[Scopus]:1  IF:3.3/3.3 | Submit date：2024/01/02
Cancer Metabolism  Combination Therapy  Hk2  Nsclc  Pdk1  
Co-delivery of dimeric camptothecin and chlorin e6 via polypeptide-based micelles for chemo-photodynamic synergistic therapy Journal article
Guo, Zhaopei, Wong, Ka Hong, Li, Enze, Zhou, Xingzhi, Jiang, Di, Gao, Jiebing, Chen, Meiwan. Co-delivery of dimeric camptothecin and chlorin e6 via polypeptide-based micelles for chemo-photodynamic synergistic therapy[J]. Chinese Medicine (United Kingdom), 2023, 18(1), 133.
Authors:  Guo, Zhaopei;  Wong, Ka Hong;  Li, Enze;  Zhou, Xingzhi;  Jiang, Di; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:5.3/5.5 | Submit date：2024/01/02
Camptothecin  Chemo-photodynamic Therapy  Combination Cancer Therapy  Polypeptide  
A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov Journal article
Yang, Jing, Kang, Heming, Lyu, Liyang, Xiong, Wei, Hu, Yuanjia. A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov[J]. Discover Oncology, 2023, 14(1), 151.
Authors:  Yang, Jing;  Kang, Heming;  Lyu, Liyang;  Xiong, Wei;  Hu, Yuanjia
Favorite | TC[WOS]:8 TC[Scopus]:7 | Submit date：2023/09/21
Bispecific Antibodies  Combination Therapy  Immuno-oncology Therapy  Kinase Inhibitors  Pd-1/pd-l1 Inhibitors  Targeted Therapy  
Epigallocatechin gallate circumvents drug induced resistance in non-small cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis Journal article
Zhou, Yan, Huang, Shiqi, Guo, Yizhen, Ran, Maxoin, Shan, Wenying, Wen-Hau Chen, Tam, Kin Yip. Epigallocatechin gallate circumvents drug induced resistance in non-small cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axis[J]. Phytotheraphy Research, 2023, 37(12), 5837-5853.
Authors:  Zhou, Yan;  Huang, Shiqi;  Guo, Yizhen;  Ran, Maxoin;  Shan, Wenying; et al.
Favorite | TC[WOS]:6 TC[Scopus]:8  IF:6.1/7.0 | Submit date：2023/08/22
Acquired Drug Resistance  Combination Therapy  Egcg  Egfr-tkis  Nsclc  Synergetic Effect  
Active Ingredients from Chinese Medicine for Combination Cancer Therapy Journal article
Xuan Wang, Jing Li, Ruie Chen, Ting Li, Meiwan Chen. Active Ingredients from Chinese Medicine for Combination Cancer Therapy[J]. International Journal of Biological Sciences, 2023, 19(11), 3499-3525.
Authors:  Xuan Wang;  Jing Li;  Ruie Chen;  Ting Li;  Meiwan Chen
Favorite | TC[WOS]:14 TC[Scopus]:14  IF:8.2/8.3 | Submit date：2023/08/21
Nanomedicine  Chinese Medicine  Active Ingredients  Combination Cancer Therapy  
Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation Journal article
Zhou,Jing Bo, Tang,Dongyang, He,Lin, Lin,Shiqi, Lei,Josh Haipeng, Sun,Heng, Xu,Xiaoling, Deng,Chu Xia. Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation[J]. Pharmacological Research, 2023, 194, 106830.
Authors:  Zhou,Jing Bo;  Tang,Dongyang;  He,Lin;  Lin,Shiqi;  Lei,Josh Haipeng; et al.
Favorite | TC[WOS]:8 TC[Scopus]:8  IF:9.1/9.0 | Submit date：2023/08/03
Bortezomib (Pubchem Cid: 387447)  Cepharanthine (Pubchem Cid: 10206)  Docetaxel (Taxotere) (Pubchem Cid: 11970251)  Drug Combination Therapy  Flunarizine Dihydrochloride (Pubchem Cid: 5282407)  Lapatinib Ditosylate (Pubchem Cid: 9941095)  Machine Learning  Pazopanib Hydrochloride (Pubchem Cid: 11525740)  Potential Combination Biomarkers  Tamoxifen Citrate (Pubchem Cid: 2733525)  Three-dimensional Tumor Slice Culture  Vatalanib (Pubchem Cid: 151194)  Vincristine (Pubchem Cid: 5978)  Xl-184 (Cabozantinib) (Pubchem Cid: 25102847)